CoChat
Sign Up
Cited by 212Treatment of Major DepressionTryptophan and brain disordersSchizophrenia research and treatment

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Minocycline as adjunctive therapy for patients with unipolar psychotic depression: An open-label study

Miyaoka, Tsuyoshi, Wake, Rei, Furuya, Motohide, Liaury, Kristian, Ieda, Masa, Kawakami, Kazunori, Tsuchie, Keiko, Taki, Michiyo, Ishihara, Kotomi, Araki, Tomoko, Horiguchi, Jun·2012·Progress in Neuro-Psychopharmacology and Biological Psychiatry
DOI 10.1016/j.pnpbp.2012.02.002
Open this paper in CoChat — free account

Abstract

Background Approximately 25% of patients admitted to a hospital as a result of depression are actually suffering from psychotic depression. Psychotic symptoms can be present in patients with either unipolar depression or bipolar depression and can be difficult to treat. It was reported the second-generation tetracycline may exert potential antidepressant effects through its robust neuroprotective activities, which include neurogenesis, antioxidation, and anti-glutamate excitotoxicity, and may direct regulation of pro-inflammatory agents.Methods This was a 6-week, open-label study to evaluate the efficacy and safety of minocycline in combination with antidepressants in adult inpatients (n=25) diagnosed with major depression with psychotic features (psychotic depression) according to DSM-IV-TR. The primary endpoint was the change from baseline in the Hamilton Depression Rating Scale (HAM-D-21) score from baseline to week 6. Secondary endpoints were changes in the Brief Psychiatric Rating Scale (BPRS) and the Clinical Global Impression (CGI) Scale scores from baseline to week 6. Spontaneously reported adverse events were recorded.Results The patients' average age was 46.9±10.2 years. Minocyline (150 mg/day) in combination with antidepressants (fulvoxamine, paroxetine, and sertraline) provided significant improvement in depression. Mean (± SD) HAM-D-21 was reduced to 6.7±1.9 at week 6 from a baseline value of 40.4±2.5. Significant improvement of psychotic symptoms (mean±SD) was indicated by the decrease in BPRS scores from baseline (63.3±8.7) to week 6 (4.6±2.4). No serious adverse events occurred.Conclusions These preliminary data suggest that minocycline in combination with antidepressants is effective and well tolerated in the treatment of unipolar psychotic depression. Further studies using larger, double-blind, parallel-group design are warranted to confirm these findings.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.pnpbp.2012.02.002

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 42 references

Research works printed but not linked: 1

  1. Arakawa, 2012, Minocycline produced antidepressant-like effects on the learned helplessness rats with alterations in levels of monoamine in the amygdale and no changes in BDNF levels in the hippoicampus at baseline, Prog Neuropsychopharmacol Biol Psychiatry, 100, 601

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Miyaoka, T., Wake, R., Furuya, M., Liaury, K., Ieda, M., Kawakami, K., Tsuchie, K., Taki, M., Ishihara, K., Araki, T., & Horiguchi, J.
Affiliations
Shimane University (JP)
Corresponding author
Miyaoka, Tsuyoshi
ORCID
Venue
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Publisher
Elsevier BV
Published
2012-06
Volume
37
Issue
2
Pages
222-226
ISSN
0278-5846 (ISSN-L)
DOI
10.1016/j.pnpbp.2012.02.002
OpenAlex
W2002519510
Cited by
212
References
42
Citations by year
2026: 3 · 2025: 8 · 2024: 10 · 2023: 6 · 2022: 16 · 2021: 15 · 2020: 17 · 2019: 16 · 2018: 13 · 2017: 28 · 2016: 23 · 2015: 26 · 2014: 11 · 2013: 13 · 2012: 5
FWCI
12.94
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Progress in Neuro-Psychopharmacology and Biological Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Funders
Ministry of Education, Culture, Sports, Science and Technology
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Keywords
minocycline, psychotic depression, major depressive disorder, adjunctive therapy, antidepressants, paroxetine, sertraline, neuroprotection, neurogenesis, anti-inflammatory activity, antidepressant efficacy, drug safety
MeSH terms
Adult, Antidepressive Agents, Depressive Disorder, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Minocycline, Psychotic Disorders, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review